N E Samalavicius1,2,3, A Dulskas4,5, V Janusonis1, V Klimasauskiene6, V Eismontas1, O Deduchovas1, T Janusonis7,8, R Markelis9, E Smolskas10. 1. Department of Surgery, Klaipeda University Hospital, 41 Liepojos Str, LT-92288, Klaipeda, Lithuania. 2. Clinic of Internal, Family Medicine and Oncology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. 3. Health Research and Innovation Science Center, Faculty of Health Sciences, Klaipeda University, Klaipeda, Lithuania. 4. Clinic of Internal, Family Medicine and Oncology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. audrius.dulskas@gmail.com. 5. Department of Abdominal and General Surgery and Oncology, National Cancer Institute, 1 Santariskiu Str., LT-08406, Vilnius, Lithuania. audrius.dulskas@gmail.com. 6. Deraptament of Surgery, Republican Vilnius University Hospital, Vilnius, Lithuania. 7. Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. 8. Department of Anesthesiology and Intensive Care, Klaipeda University Hospital, Klaipeda, Lithuania. 9. Department of Surgery, Hospital of Oncology of Lithuanian, University of Health Sciences Kaunas Clinics, Kaunas, Lithuania. 10. Department of Surgery, Vilnius City Clinical Hospital, Vilnius, Lithuania.
Abstract
BACKGROUND: The aim of this study was to evaluate the initial experience of a single robotic center with the Senhance® robotic systems (TransEnterix Surgical Inc, Morrisville, NC, USA) in colorectal surgery. METHODS: We performed a retrospective analysis of prospectively collected data of patients who underwent colorectal surgery using the Senhance® robotic systems, from November 2018 to November 2020. Perioperative, intraoperative, and short-term postoperative data were assessed. RESULTS: There were 57 patients (28 women and 29 men, mean age 61.7 ± 6.2 years [range 23-84 years]). Forty-eight (84.2%) patients underwent surgery for colorectal cancer (22 colon cancer and 26 rectal cancer) and 9 (15.8%) for benign conditions. Mean operating time was 194 min ± 57.8 min (range 90-380 min). In total, 27(47.4%) operations were performed on the colon and 30 (52.6%) on the rectum; mean length of postoperative hospital stay was 8 ± 6.2 days (range 3-48 days). There were 2 (3.4%) conversions to open surgery. No intraoperative complications occurred. Seven patients (12.3%) had postoperative complications 3 (5.3%) of whom had to be treated under general anesthesia. There was no mortality. In 48 patients operated on for colorectal cancer, the mean lymph-node harvest was 18 ± 7.9 (range 7-38 lymph nodes). In the rectal cancer group of 26 patients, the distal resection margin was 3.3 ± 1.8 cm. CONCLUSIONS: In our experience, surgery using the new Senhance® robotic system was safe and feasible in surgery of the colon and rectum. Randomized controlled trials comparing this type of colorectal surgery with laparoscopic and/or other types of robotic surgery are needed.
BACKGROUND: The aim of this study was to evaluate the initial experience of a single robotic center with the Senhance® robotic systems (TransEnterix Surgical Inc, Morrisville, NC, USA) in colorectal surgery. METHODS: We performed a retrospective analysis of prospectively collected data of patients who underwent colorectal surgery using the Senhance® robotic systems, from November 2018 to November 2020. Perioperative, intraoperative, and short-term postoperative data were assessed. RESULTS: There were 57 patients (28 women and 29 men, mean age 61.7 ± 6.2 years [range 23-84 years]). Forty-eight (84.2%) patients underwent surgery for colorectal cancer (22 colon cancer and 26 rectal cancer) and 9 (15.8%) for benign conditions. Mean operating time was 194 min ± 57.8 min (range 90-380 min). In total, 27(47.4%) operations were performed on the colon and 30 (52.6%) on the rectum; mean length of postoperative hospital stay was 8 ± 6.2 days (range 3-48 days). There were 2 (3.4%) conversions to open surgery. No intraoperative complications occurred. Seven patients (12.3%) had postoperative complications 3 (5.3%) of whom had to be treated under general anesthesia. There was no mortality. In 48 patients operated on for colorectal cancer, the mean lymph-node harvest was 18 ± 7.9 (range 7-38 lymph nodes). In the rectal cancer group of 26 patients, the distal resection margin was 3.3 ± 1.8 cm. CONCLUSIONS: In our experience, surgery using the new Senhance® robotic system was safe and feasible in surgery of the colon and rectum. Randomized controlled trials comparing this type of colorectal surgery with laparoscopic and/or other types of robotic surgery are needed.